Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Leirisalo

Showing results (231-240 of 281) with videos related to

Pageof 29
Sort By:
Genes and Immunity|July 9, 2003
Analysis of MHC region genetics in Finnish patients with juvenile idiopathic arthritis: evidence for different locus-specific effects in polyarticular vs pauciarticular subsets and a shared DRB1 epitopeJ A Runstadler, H Säilä, A Savolainen, et al.
Diabetes Care|July 1, 1993
Seven years of remission in a type I diabetic patientV A Koivisto, M Leirisalo-Repo, P Ebeling, et al.
Clinical and Experimental Rheumatology|May 21, 2010
Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitisE Martín-Mola, J Sieper, M Leirisalo-Repo, et al.
Scandinavian Journal of Rheumatology|April 17, 2008
Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progressionM Hakala, J Risteli, S Aman, et al.
Scandinavian Journal of Rheumatology|March 11, 2009
Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritisK Puolakka, H Kautiainen, T Mottonen, et al.
Scandinavian Journal of Rheumatology|June 23, 2025
Limited reduction of bone mineral density in patients with early rheumatoid arthritis receiving aggressive treatment: 10 year results of the NEO-RACo studyT Sandström, O Kaipiainen-Seppänen, M Mali, et al.
Clinical and Experimental Rheumatology|May 18, 2005
Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drugA Kuuliala, M Leirisalo-Repo, T Möttönen, et al.
Rheumatology (Oxford, England)|December 22, 2004
How aggressive should initial therapy for rheumatoid arthritis be? The Finnish experienceK Kaarela, M Hakala, P Hannonen, et al.
Arthritis Research & Therapy|November 21, 2022
The biological activity of serum bacterial lipopolysaccharides associates with disease activity and likelihood of achieving remission in patients with rheumatoid arthritisJ Parantainen, G Barreto, R Koivuniemi, et al.
Clinical and Experimental Rheumatology|December 15, 2007
Serum IL-1beta levels are associated with the presence of erosions in recent onset rheumatoid arthritisK K Eklund, M Leirisalo-Repo, P Ranta, et al.
Pageof 29

Showing results (231-240 of 281) with videos related to

Sort By:
Pageof 29
Genes and Immunity|July 9, 2003
Analysis of MHC region genetics in Finnish patients with juvenile idiopathic arthritis: evidence for different locus-specific effects in polyarticular vs pauciarticular subsets and a shared DRB1 epitopeJ A Runstadler, H Säilä, A Savolainen, et al.
Diabetes Care|July 1, 1993
Seven years of remission in a type I diabetic patientV A Koivisto, M Leirisalo-Repo, P Ebeling, et al.
Clinical and Experimental Rheumatology|May 21, 2010
Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitisE Martín-Mola, J Sieper, M Leirisalo-Repo, et al.
Scandinavian Journal of Rheumatology|April 17, 2008
Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progressionM Hakala, J Risteli, S Aman, et al.
Scandinavian Journal of Rheumatology|March 11, 2009
Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritisK Puolakka, H Kautiainen, T Mottonen, et al.
Scandinavian Journal of Rheumatology|June 23, 2025
Limited reduction of bone mineral density in patients with early rheumatoid arthritis receiving aggressive treatment: 10 year results of the NEO-RACo studyT Sandström, O Kaipiainen-Seppänen, M Mali, et al.
Clinical and Experimental Rheumatology|May 18, 2005
Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drugA Kuuliala, M Leirisalo-Repo, T Möttönen, et al.
Rheumatology (Oxford, England)|December 22, 2004
How aggressive should initial therapy for rheumatoid arthritis be? The Finnish experienceK Kaarela, M Hakala, P Hannonen, et al.
Arthritis Research & Therapy|November 21, 2022
The biological activity of serum bacterial lipopolysaccharides associates with disease activity and likelihood of achieving remission in patients with rheumatoid arthritisJ Parantainen, G Barreto, R Koivuniemi, et al.
Clinical and Experimental Rheumatology|December 15, 2007
Serum IL-1beta levels are associated with the presence of erosions in recent onset rheumatoid arthritisK K Eklund, M Leirisalo-Repo, P Ranta, et al.
Pageof 29